Molecular Property Design: Does Everyone Get It?

ACS Medicinal Chemistry Letters

Volumn 6, Issue 7, 2015, Pages 722-725

  Leeson, Paul D ^a   Young, Robert J ^b  

^a Paul Leeson Consulting Ltd Malt House   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG DESIGN; DRUG INDUSTRY; DRUG METABOLISM; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIPOPHILICITY; MOLECULAR INTERACTION; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SYNTHESIS;

EID: 84938495908     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00157     Document Type: Article

References (15)

1. Hansch, C.; Björkroth, J. P.; Leo, A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design J. Pharm. Sci. 1987, 76, 663-687
2. Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121
3. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
4. Leeson, P. D.; St-Gallay, S. A. The influence of the 'organizational factor' on compound quality in drug discovery Nat. Rev. Drug Discovery 2011, 10, 749-765
5. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of ion class and time on oral drug molecular properties MedChemComm 2011, 2, 91-105
6. Young, R. J.; Green, D. V.; Luscombe, C. N.; Hill, A. P. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity Drug Discovery Today 2011, 16, 822-830
7. Perola, E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 2010, 53, 2986-2997
8. Morgan, P.; Van Der Graaf, P. H.; Arrowsmith, J.; Feltner, D. E.; Drummond, K. S.; Wegner, C. D.; Street, S. D. A. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival Drug Discovery Today 2012, 17, 419-424
9. Cook, D.; Brown, D.; Alexander, R.; March, R.; Morgan, P.; Satterthwaite, G.; Pangalos, M. N. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework Nat. Rev. Drug Discovery 2014, 13, 419-431
10. Treiselmann, T.; Wagner, H.; Fuchs, K.; Hamprecht, D. W.; Berta, D. G.; Cremonesi, P.; Streicher, R.; Luippold, G.; Volz, A.; Markert, M.; Nar, H. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives J. Med. Chem. 2014, 57, 8766-76
11. Cumming, J. G.; Davis, A. M.; Muresan, S.; Haeberlein, M.; Chen, H. Chemical predictive modelling to improve compound quality Nat. Rev. Drug Discovery 2013, 12, 948-962
12. Lipinksi, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
13. Higueruelo, A. P.; Schreyer, A. G.; Bickerton, G. R. J.; Blundell, T. L.; Pitt, W. R. What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics? PLoS One 2012, 7 (12) e51742
14. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; Zhang, W.; Xie, X.; Yang, H.; Jiang, H.; Cherezov, V.; Liu, H.; Stevens, R. C.; Zhao, Q.; Wu, B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex Science 2013, 341, 1387-1390
15. Cheshire, D. R. How well do medicinal chemists learn from experience? Drug Discovery Today 2011, 16, 817-821